Plant-based vaccines are derived from antigens produced in genetically modified plants that can be extracted and purified by conventional methods. These vaccines can either be consumed or applied to mucosal surfaces. Plants that are commonly used in production of vaccines are tobacco, potato, tomato, corn, and rice. Currently, there are several transgenic plants used in development of four different types of vaccines namely: viral vaccines, parasite vaccines, and bacterial vaccines.
Plant-based vaccines can be extensively manufactured at a very cheap cost. Currently, no plant-based vaccine has received approval from the US Food and Drug Administration (FDA), as these vaccines are classified under the genetically modified crop category. However, there are several plant-based vaccines in clinical trials, which are expected to receive approval from FDA during the forecast period.
Plant-Based Vaccines Market Drivers
Increasing number of research and development activities by key players in the market and robust pipeline of plant-based vaccines is expected to be a major factor driving the global plant-based vaccines market growth during the forecast period. For instance, in 2017, Medicago Inc.—a Canada-based biopharmaceutical company that focuses on development of plant-based vaccines—initiated phase 3 clinical trial to evaluate efficacy of its seasonal quadrivalent influenza vaccine (QIV) candidate. The trial comprises around 10,000 subjects in the following countries: the U.S., Canada, Germany, the U.K., the Philippines, Finland, and Thailand. QIV was developed using a new virus-like particle (VLP) technology, which is an alternative to egg-based and cell-based production systems.
Furthermore, in 2017, researchers from the Arizona State University (ASU), in the U.S., developed the first plant-based Zika vaccine. According to the university, the newly developed plant-based Zika vaccine is safer, potent, and its production cost is much cheaper. Such robust pipeline of plant-based vaccines is expected to be a major factor in growth of the global plant-based vaccines market during the forecast period.
Moreover, various government initiatives for development of plant-based vaccines are also expected to fuel the plant-based vaccines market growth during the forecast period. For instance, in 2015, Public Health Agency of Canada (PHAC) granted a contract to Medicago Inc. for development of two plant-based vaccines for Sudan strain of Ebola virus.
High prevalence of viruses such as Influenza, Zika virus, and Ebola is expected to increase demand for plant-based vaccines, which in turn is expected to propel growth of the plant-based vaccines market. For instance, according to a report published by Centers for Disease Control and Prevention (CDC), in October 2016, around 140,000 to 710,000 influenza related patients were hospitalized and around 12,000 to 56,000 influenza related deaths were registered, since 2010.
According to a report by the International Journal of Topical Disease & Health, in 2016, between1976-2015, there were around 24 outbreaks of Ebola virus disease in several regions of West-African countries. The most recent outbreak in 2015, reported around 24,350 cases and around 10,004 deaths.
Plant-Based Vaccines Market Regional Analysis
North America is expected to be dominant in the global plant vaccines market over the forecast period. This is owing to high prevalence of infectious disease such as Ebola and Influenza in the region. For instance, according to a study by Influenza Research Center, 2014, influenza is responsible for substantial morbidity and mortality, with an average of over 100,000 hospitalizations and around 20,000 deaths, annually in the U.S.
Asia Pacific plant-based vaccines market is expected to show significant growth during the forecast period, owing to increasing number of collaborations and acquisitions between key players in the region. For instance, in 2013, Japan-based pharmaceutical company—Mitsubishi Tanabe Pharma Corporation—acquired Medicago Inc., a Canada-based biopharmaceutical company, focused on development of new plant-based vaccines. Furthermore, Mitsubishi Tanabe Pharma Corporation acquired 60% share of Medicago Inc. at total amount of US$ 357 million. The other 40% share is owned by an investment group, Philip Morris Investments B.V.
Plant-Based Vaccines Market Key Players
Key players operating in the global plant-based vaccines market include Medicago Inc., Mitsubishi Tanabe Pharma Corporation, iBio, Inc., Fraunhofer Center for Molecular Biotechnology (CMB), Protalix BioTherapeutics, and others.
Plant-Based Vaccines Market Taxonomy:
The global plant based vaccines market is segmented on the basis of vaccine type, application, and region
By Vaccine Type-
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.